-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Preventing Relapse after CD19-CAR T-cell Therapy for Pediatric ALL: Role of Transplant and Enhanced CAR T cells

Program: Education Program
Session: CAR T Cells in ALL: Bridge or Definitive Therapy?
Hematology Disease Topics & Pathways:
Biological therapies, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Therapies, Immunotherapy
Saturday, December 9, 2023, 9:30 AM-10:45 AM

Stephen Gottschalk, MD

St. Jude's, Memphis, TN; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN

Disclosures: Gottschalk: Sanofi: Consultancy; TESSA Therapeutics: Consultancy; Immatics: Other: Member of the Data Safety Monitoring Board; BeBiopharma: Membership on an entity's Board of Directors or advisory committees.

See more of: CAR T Cells in ALL: Bridge or Definitive Therapy?
See more of: Education Program
<< Previous Presentation | Next Presentation